We are monitoring the impact of COVID-19 on APAC Liver Disease Treatment Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1653
Share on
Share on

Asia Pacific Liver Disease Treatment Market Research Report – Segmented By Treatment Modality, Disease Type and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1653
Pages: 145

APAC Liver Disease Treatment Market Size (2021 to 2026)

The size of the Liver Disease Treatment Market in the Asia Pacific is expected to reach USD 3.04 billion by 2026 from USD 1.69 billion in 2021, growing at a CAGR of 12.51% during the forecast period.

APAC's liver disease treatment market is predicted to be driven by factors such as the growing R&D investment, disorganized lifestyle, growing public awareness, the aging population, and unmet demands for liver cancer treatment. As a result of the surge in alcohol consumption, liver cirrhosis is on the rise. According to the World Health Organization, alcohol intake leads to liver cirrhosis in 20% to 50% of people. In addition, obesity has increased the risk of non-alcoholic fatty liver disease, characterized by fat accumulation in the liver. There have been more obese people since 1980.

Due to the increasing prevalence of liver disorders in Asia-Pacific, governments and non-profit organizations play a growing role in raising awareness about liver disorders. As a result, these organizations are dedicated to raising awareness about liver disorders and providing funding for research and development into the prevention, treatment, and cure of liver diseases.

Various medication approvals and the commercialization of numerous anticipated pipeline pharmaceuticals are also projected to boost the market's growth.

With the rising frequency of liver illnesses, liver disease treatment has changed quickly. As a result, several treatment alternatives are available on the market, most of which aim to avoid the course of liver disease and reduce the risk of liver morbidity and death. Furthermore, regional market growth is likely to be fuelled by rising patient awareness and the release of innovative products that address unmet medical requirements throughout the forecast period.

There is fierce competition from alternative medicine (herbal, natural medicine) and side-effects caused by the product (fatigue, fever, and depression). In addition, APAC Liver Disease Treatment market growth is also hindered by the high cost of the drugs.

This research report on the APAC liver disease treatment market has been segmented and sub-segmented into the following categories:

By Treatment Modality:

  • Antiviral
  • Vaccines
  • Chemotherapy
  • Immunosuppressive Agents
  • Corticosteroids

By Disease Type:

  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Alcohol-Induced
  • Liver Cancer

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, APAC is one of the most lucrative regional markets in the global market. Liver disease can be life-threatening since it can lead to various acute and chronic illnesses (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumor, and liver cirrhosis, among others). Nausea, exhaustion, diarrhea, jaundice, bloated belly, and mental confusion are the first signs of liver impairment. Therefore, Asia-Pacific is the fastest-growing market for Liver Disease Treatment Drugs. According to a recent survey, Hepatitis affects 7% of the population in China, with many people in danger of developing chronic liver cancer and cirrhosis. Non-Alcoholic Fatty Liver Disease is also a problem.

Japan is stimulating market expansion because of approved government actions linked to drug cost adjustment and new pharmaceuticals for liver disease treatments. The variables mentioned above contribute to the region's market expansion. In addition, the market demand is fuelled by increased healthcare infrastructure requirements, rising hepatitis, and hepatocellular cancer.

Around 1 million people in India have recently been diagnosed with liver cirrhosis. The rise in the number of obese and diabetic people doubles market growth. The liver disease treatment industry in the area is being fuelled by a changing lifestyle and increased economic prosperity.

KEY MARKET PLAYERS:

Companies playing a significant role in the Asia Pacific liver disease treatment market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

  1. Research Methodology

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

  1. Overview

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

  1. Market Segmentation

                5.1 Treatment Modality                               

                                5.1.1 Introduction           

                                5.1.2 Antiviral    

                                5.1.3 Vaccines   

                                5.1.4 Chemotherapy      

                                5.1.5 Immunosuppressive Agents           

                                5.1.6 Corticosteroids      

                                5.1.7 Others      

                                5.1.8  Y-o-Y Growth Analysis, By Product              

                                5.1.9  Market Attractiveness Analysis, By Product            

                                5.1.10 Market Share Analysis, By Product             

                5.2 Disease Type                             

                                5.2.1 Introduction           

                                5.2.2 Hepatitis  

                                5.2.3 Non-Alcoholic Fatty Liver Disease 

                                5.2.4 Alcohol Induced    

                                5.2.5 Liver Cancer            

                                5.2.6 Others      

                                5.2.7  Y-o-Y Growth Analysis, By Type    

                                5.2.8  Market Attractiveness Analysis, By Type  

                                5.2.9  Market Share Analysis, By Type    

  1. Geographical Analysis

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Type

                                                6.1.3.4 By Application

                                                6.1.3.5 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Type

                                                6.1.4.4 By Application

                                                6.1.4.5 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Type

                                                6.1.5.4 By Application

                                                6.1.5.5 By Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Gilead Science Inc                    

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 Merck & Co.                               

                8.4 Johnson & Johnson                 

                8.5 Novartis                       

                8.6 Roche                           

                8.7 Sanofi-Aventis                          

                8.8 Abbott Laboratories                               

                8.9 Bayer Schering AG                   

                8.10 AstraZeneca                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

  1. a) List of Tables
  2. b) List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Antiviral Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Immunosuppressive Agents Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Corticosteroids Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Hepatitis Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Non-Alcoholic Fatty Liver Disease Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Alcohol Induced Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Liver Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  14. Japan Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  15. Japan Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)
  16. China Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  17. China Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)
  18. India Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  19. India Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. Australia Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  21. Australia Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)
  22. South Korea Liver Disease Treatment Market, By Treatment Modality , From 2021 to 2026 (USD Billion)
  23. South Korea Liver Disease Treatment Market, By Disease Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample